Sanofi licenses CRISPR enzyme to develop new sickle cell cure; brewing battle between a government and drug industry

Taking stock of the drug industry, from the lab to the medicine chest

July 17, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Molly Ferguson for STAT STAT+ | Colombian government explores compulsory licensing for an HIV drug By exploring a compulsory license for ViiV's HIV medicine, Colombia is setting up another battle with the pharmaceutical industry. By Ed Silverman STAT+ | Detailed data confirm benefits — and risks — of Eli Lilly's Alzheimer's drug The data, while positive, leave physicians with lingering questions about the Alzheimer's drug's impact on patients. By Adam Feuerstein STAT+ | BridgeBio heart drug succeeds in pivotal study The results may give the medicine, acoramidis, a path to the market after a failure that led its maker's stock to plunge in December 2021. By Matthew Herper Ruby Wallau for STAT STAT+ | Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure Sanofi licensed a CRISPR enzyme from a Jennifer Doudna startup in a bid to develop a safer, simpler and more scalable cure for sickle cell. By Jason Mast FDA approves RSV monoclonal antibody for infants, young children at high risk Use of the antibody treatment, the brand name for which is Beyfortus, still needs to be recommended by the ACIP. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser